PregLem acquires additional rights to ulipristal
This article was originally published in Scrip
Executive Summary
PregLem, the Swiss biopharmaceutical company, has acquired the rights to develop and commercialise HRA Pharma's ulipristal acetate for benign gynaecological disorders in North America.